Research in animals suggests that sclerostin may be a potential target for the treatment of conditions of characterized by low BMD and increased risk of fractures, such as osteoporosis (Krishnan et al., 2006; Pietrzyk et al., 2017), and sclerostin is being investigated as a treatment for post-menopausal osteoporosis (Lewiecki, 2011). This evidence concerns the gene SOST and osteoporosis.